Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28485102 | 0.78 | KIF11 (0.52) | KIF11CYP2A6LOXL2CYP19A1ALDH1A1 | |
| SCHEMBL241243 | 0.78 | KIF11 (0.42) | KIF11CYP2A6LOXL2CYP19A1ALDH1A1 | |
| SCHEMBL830678 | 0.77 | PYCR1 (0.37) | MAPTCYP2A6ALDH1A1TSHRATM | |
| SCHEMBL13246739 | 0.77 | TACR1 (0.41) | KIF11ALDH1A1TSHRATMHTT | |
| SCHEMBL7025558 | 0.74 | KIF11 (0.55) | KIF11CYP2A6LOXL2CYP19A1ALDH1A1 | |
| SCHEMBL8479151 | 0.74 | KIF11 (0.55) | KIF11CYP2A6LOXL2CYP19A1ALDH1A1 | |
| SCHEMBL7025554 | 0.74 | KIF11 (0.55) | KIF11CYP2A6LOXL2CYP19A1ALDH1A1 | |
| SCHEMBL156260 | 0.73 | KIF11 (0.59) | KIF11CYP2A6LOXL2CYP19A1ALDH1A1 | |
| SCHEMBL838589 | 0.72 | ATM (0.33) | MAPTALDH1A1TSHRATMHTT | |
| SCHEMBL26394625 | 0.72 | KIF11 (0.53) | KIF11CYP2A6LOXL2CYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143451-B2 | Reacting a ketone with an allyl boron compound anc ammonia or ammonium salt; synthons | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2012-03-27 | — | — | US | disclosed |
| US-8143451-B2 | Reacting a ketone with an allyl boron compound anc ammonia or ammonium salt; synthons | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2012-03-27 | — | — | US | disclosed |
| US-20080139847-A1 | METHODS OF PREPARING TERTIARY CARBINAMINE COMPOUNDS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-06-12 | — | — | US | disclosed |
| US-20080139847-A1 | METHODS OF PREPARING TERTIARY CARBINAMINE COMPOUNDS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139847-A1 | METHODS OF PREPARING TERTIARY CARBINAMINE COMPOUNDS | INMT, CROCC, GNMT | KIF11 1608/4885MAPT 3624/4885CYP2A6 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.